|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Gastrointestinal cancer
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
Keun-Wook Lee, Dae Young Zang, Min-Hee Ryu, Hye Sook Han, Ki Hyang Kim, Mi-Jung Kim, Sung Ae Koh, Sung Sook Lee, Dong-Hoe Koo, Yoon Ho Ko, Byeong Seok Sohn, Jin Won Kim, Jin Hyun Park, Byung-Ho Nam, In Sil Choi
Cancer Res Treat.
2023;55(4):1250-1260. Published online May 25, 2023 DOI:
https://doi.org/10.4143/crt.2023.333
BCL2 Regulation according to Molecular Subtype of Breast Cancer by Analysis of The Cancer Genome Atlas Database
Ki-Tae Hwang, Kwangsoo Kim, Ji Hyun Chang, Sohee Oh, Young A Kim, Jong Yoon Lee, Se Hee Jung, In Sil Choi
Cancer Res Treat.
2018;50(3):658-669. Published online July 4, 2017 DOI:
https://doi.org/10.4143/crt.2017.134
Web of Science 13
Crossref 12
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
Cancer Res Treat.
2017;49(3):807-815. Published online January 18, 2017 DOI:
https://doi.org/10.4143/crt.2016.326
Web of Science 6
Crossref 6
Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
Se Hyun Kim, Kyung Hae Jung, Tae-Yong Kim, Seock-Ah Im, In Sil Choi, Yee Soo Chae, Sun Kyung Baek, Seok Yun Kang, Sarah Park, In Hae Park, Keun Seok Lee, Yoon Ji Choi, Soohyeon Lee, Joo Hyuk Sohn, Yeon-Hee Park, Young-Hyuck Im, Jin-Hee Ahn, Sung-Bae Kim, Jee Hyun Kim
Cancer Res Treat.
2016;48(4):1373-1381. Published online March 23, 2016 DOI:
https://doi.org/10.4143/crt.2015.475
Web of Science 7
Crossref 6
A Unique Case of Erdheim-Chester Disease with Axial Skeleton, Lymph Node, and Bone Marrow Involvement
Jin Lim, Ki Hwan Kim, Koung Jin Suh, Kyung Ah Yoh, Jin Young Moon, Ji Eun Kim, Eun Youn Roh, In Sil Choi, Jin-Soo Kim, Jin Hyun Park
Cancer Res Treat.
2016;48(1):415-421. Published online February 26, 2015 DOI:
https://doi.org/10.4143/crt.2014.160
Web of Science 8
Crossref 8
Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer
In Sil Choi, Do-Youn Oh, Byoung-Su Kim, Keun-Wook Lee, Jee Hyun Kim, Jong-Seok Lee
Cancer Res Treat.
2007;39(3):99-103. Published online September 30, 2007 DOI:
https://doi.org/10.4143/crt.2007.39.3.99
Crossref 19
Open-label, Randomized Comparison of the Efficacy of Intravenous Dolasetron Mesylate and Ondansetron in the Prevention of Acute and Delayed Cisplatin-induced Emesis in Cancer Patients
Jin-Soo Kim, Ji Yeon Baek, Sook Ryun Park, In Sil Choi, Sang-Il Kim, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
Cancer Res Treat.
2004;36(6):372-376. Published online December 31, 2004 DOI:
https://doi.org/10.4143/crt.2004.36.6.372
Crossref 2
Discrepancies of the Values on the Withholding Futile Interventions between Physician and Family Members of Terminal Cancer Patients
Do Youn Oh, Mi Ra Kim, In Sil Choi, Yo Han Joh, Byung Su Kim, Do Yeun Kim, Jee Hyun Kim, Se Hoon Lee, Tae You Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim
Cancer Res Treat.
2001;33(4):350-356. Published online August 31, 2001 DOI:
https://doi.org/10.4143/crt.2001.33.4.350
1
Journal Impact Factor 4.6